Photocure ASA: Board Update

Published: 9 August 2013Organisational Announcements

Oslo, Norway, August 8, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that Ingrid Wiik, a member of Photocure's board of director's since 2011, has sadly passed away.

Åse Aulie Michelet, Chairman of the Board of Photocure said, "On behalf of the Board of Directors and the employees of Photocure, we extend our deepest sympathies to Ingrid's family. Ingrid has played an integral role in the growth and success of Photocure and we thank her for the many contributions she has made."

Ingrid Wiik has spent more than 40 years in the pharmaceutical industry, both in R&D and general management, and has extensive leadership and international experience. She was President and CEO of Alpharma Inc. (listed on NYSE). She has also held several board positions including: Algeta ASA, Diagenic ASA, Coloplast AS (Denmark), Human Care (Sweden), Norske Skog ASA, Biotec Pharmacon ASA, Statoil ASA and Alpharma Inc.

For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events